Parkman Healthcare Partners’s Nurix Therapeutics NRIX Stock Holding History

Parkman Healthcare Partners’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-228,271	Closed	-$2.6M	–	98
2025 Q2	$2.6M	Sell	228,271 -122,149	-35%	-$1.32M	0.3%	76
2025 Q1	$4.16M	Sell	350,420 -181,752	-34%	-$3.04M	0.49%	57
2024 Q4	$10M	Buy	532,172 +93,201	+21%	+$2.14M	1.34%	30
2024 Q3	$9.86M	Sell	438,971 -35,708	-8%	-$809K	1.26%	27
2024 Q2	$9.91M	Buy	474,679 +224,679	+90%	+$3.5M	1.33%	27
2024 Q1	$3.67M	Buy	+250,000	New	+$2.69M	0.45%	66
2022 Q2	–	Sell	-20,663	Closed	-$289K	–	85
2022 Q1	$289K	Sell	20,663 -67,161	-76%	-$1.19M	0.08%	79
2021 Q4	$2.54M	Buy	+87,824	New	+$2.66M	0.56%	48

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parkman Healthcare Partners's NRIX Position: Q3 2025 in Review

Parkman Healthcare Partners sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 228,271 shares — an estimated $2.6M sold.

Parkman Healthcare Partners first reported a position in NRIX in Q4 2021 and held it in 8 quarters. The position peaked at $10M in Q4 2024. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

Parkman Healthcare Partners reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 228,271 Nurix Therapeutics shares in Q3 2025, an estimated $2.6M.
Parkman Healthcare Partners first reported a position in Nurix Therapeutics in Q4 2021 and held it in 8 quarters.
Parkman Healthcare Partners's Nurix Therapeutics position peaked at $10M in Q4 2024.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.